{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:51:22Z","timestamp":1786135882839,"version":"build-2736575974"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    Late kidney allograft loss occurs through one of two mechanisms: (\n                    <jats:italic toggle=\"yes\">1<\/jats:italic>\n                    ) deterioration of kidney function leading to retransplantation or dialysis (death-censored graft loss) and (\n                    <jats:italic toggle=\"yes\">2<\/jats:italic>\n                    ) premature death with a normally functioning transplant (death with graft function)\u2014each accounting for approximately 50% of late kidney graft losses. Late death-censored graft loss typically results from a combination of immune and nonimmune events leading to common nonspecific end points (\n                    <jats:italic toggle=\"yes\">e.g<\/jats:italic>\n                    ., tubular atrophy, interstitial fibrosis, and glomerulosclerosis). Conversely, leading causes of death with graft function typically include cardiovascular events, malignancy, and infection. With an improved understanding of the multiple mechanism by which late graft dysfunction develops, there is an opportunity to identify patients at greatest risk and institute novel strategies to quell the process. Newer cardiometabolic agents with proven benefit in the general population have not been well-studied in kidney transplant recipients. However, in addition to their potential benefits in reducing cardiovascular, infectious, and malignancy end points (thus minimizing death with graft function risk), many novel agents may have additional anti-inflammatory and\/or antifibrotic benefit (minimizing death-censored graft loss risk) in the kidney transplant population. In this review, we summarize existing literature regarding major causes of death-censored graft loss and death with graft function and discuss the potential roles of new cardiorenal metabolic agents including sodium-glucose cotransport 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide 1 receptor agonists, and dual endothelin and angiotensin receptor antagonists in the kidney transplant population, including potential mechanisms to improve death with graft function and death-censored graft loss outcomes.\n                  <\/jats:p>","DOI":"10.1681\/asn.0000000726","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:21:32Z","timestamp":1744028492000},"page":"1659-1667","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies"],"prefix":"10.1681","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-5252","authenticated-orcid":false,"given":"Amanda J.","family":"Vinson","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Kidney Research Institute of Nova Scotia, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-639X","authenticated-orcid":false,"given":"Arthur","family":"Matas","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"7","key":"B1-20251209","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/TP.0000000000002961","article-title":"Late graft loss after kidney transplantation: is \u201cdeath with function\u201d really death with a functioning allograft?","volume":"104","author":"Gaston","year":"2020","journal-title":"Transplantation."},{"issue":"3","key":"B2-20251209","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant."},{"issue":"5","key":"B3-20251209","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney Int."},{"issue":"2 suppl 1","key":"B4-20251209","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","article-title":"OPTN\/SRTR 2021 annual data report: kidney","volume":"23","author":"Lentine","year":"2023","journal-title":"Am J Transplant."},{"issue":"6","key":"B5-20251209","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1600-6143.2011.03539.x","article-title":"Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success","volume":"11","author":"Lodhi","year":"2011","journal-title":"Am J Transplant."},{"issue":"12","key":"B6-20251209","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant","volume":"31","author":"Ying","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B7-20251209","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00007890-199401001-00009","article-title":"Histological findings in early routine biopsies of stable renal allograft recipients","volume":"57","author":"Rush","year":"1994","journal-title":"Transplantation."},{"issue":"11","key":"B8-20251209","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1681\/ASN.V9112129","article-title":"Beneficial effects of treatment of early subclinical rejection: a randomized study","volume":"9","author":"Rush","year":"1998","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B9-20251209","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1600-6143.2009.02727.x","article-title":"Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts","volume":"9","author":"Mengel","year":"2009","journal-title":"Am J Transplant."},{"issue":"9","key":"B10-20251209","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/j.1600-6143.2010.03240.x","article-title":"Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure","volume":"10","author":"Mannon","year":"2010","journal-title":"Am J Transplant."},{"issue":"6","key":"B11-20251209","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1172\/JCI41789","article-title":"A molecular classifier for predicting future graft loss in late kidney transplant biopsies","volume":"120","author":"Einecke","year":"2010","journal-title":"J Clin Invest."},{"issue":"9","key":"B12-20251209","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/ajt.12387","article-title":"Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: the INTERCOM study","volume":"13","author":"Halloran","year":"2013","journal-title":"Am J Transplant."},{"issue":"10","key":"B13-20251209","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2013111149","article-title":"Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection","volume":"25","author":"Loupy","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B14-20251209","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajt.2024.07.034","article-title":"Subthreshold rejection activity in many kidney transplants currently classified as having no rejection","volume":"25","author":"Halloran","year":"2025","journal-title":"Am J Transplant."},{"issue":"1","key":"B15-20251209","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation."},{"issue":"5","key":"B16-20251209","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant."},{"issue":"11","key":"B17-20251209","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.12465","article-title":"Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM)","volume":"13","author":"Halloran","year":"2013","journal-title":"Am J Transplant."},{"issue":"3","key":"B18-20251209","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ajt.2023.10.031","article-title":"The Banff 2022 kidney meeting work plan: data-driven refinement of the Banff classification for renal allografts","volume":"24","author":"Roufosse","year":"2024","journal-title":"Am J Transplant."},{"issue":"4","key":"B19-20251209","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.kint.2021.11.028","article-title":"Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics","volume":"101","author":"Loupy","year":"2022","journal-title":"Kidney Int."},{"issue":"2","key":"B20-20251209","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/TP.0000000000003012","article-title":"The causes of kidney allograft failure: more than alloimmunity. A viewpoint article","volume":"104","author":"Van Loon","year":"2020","journal-title":"Transplantation."},{"issue":"2","key":"B21-20251209","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-6143.2009.02943.x","article-title":"Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study","volume":"10","author":"Matas","year":"2010","journal-title":"Am J Transplant."},{"issue":"5","key":"B22-20251209","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.2020101418","article-title":"Data-driven derivation and validation of novel phenotypes for acute kidney transplant rejection using semi-supervised clustering","volume":"32","author":"Vaulet","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B23-20251209","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1681\/ASN.2022030290","article-title":"Data-driven chronic allograft phenotypes: a novel and validated complement for histologic assessment of kidney transplant biopsies","volume":"33","author":"Vaulet","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B24-20251209","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ajt.14431","article-title":"Renal allograft histology at 10 Years after transplantation in the Tacrolimus era: evidence of pervasive chronic injury","volume":"18","author":"Stegall","year":"2018","journal-title":"Am J Transplant."},{"issue":"suppl 2","key":"B25-20251209","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.2215\/CJN.03040707","article-title":"Late kidney allograft loss: what we know about it, and what we can do about it","volume":"3","author":"Jevnikar","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B26-20251209","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/ajt.14590","article-title":"Late graft failure after kidney transplantation as the consequence of late versus early events","volume":"18","author":"Gaston","year":"2018","journal-title":"Am J Transplant."},{"issue":"8","key":"B27-20251209","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med."},{"issue":"1","key":"B28-20251209","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1097\/TXD.0000000000000856","article-title":"Nonimmunologic donor-recipient pairing, HLA matching, and graft loss in deceased donor kidney transplantation","volume":"5","author":"Vinson","year":"2019","journal-title":"Transplant Direct."},{"issue":"6","key":"B30-20251209","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000495081","article-title":"Trends in the causes of death among kidney transplant recipients in the United States (1996-2014)","volume":"48","author":"Awan","year":"2018","journal-title":"Am J Nephrol."},{"issue":"1","key":"B31-20251209","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int."},{"issue":"12","key":"B32-20251209","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2215\/CJN.00520121","article-title":"Post-transplant cardiovascular disease","volume":"16","author":"Birdwell","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B33-20251209","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1681\/ASN.2015050524","article-title":"Relationship between eGFR decline and hard outcomes after kidney transplants","volume":"27","author":"Clayton","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"16","key":"B34-20251209","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation."},{"issue":"3","key":"B35-20251209","first-page":"251","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol Clin."},{"issue":"9","key":"B36-20251209","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation."},{"issue":"9","key":"B37-20251209","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/j.1600-6143.2012.04101.x","article-title":"Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial","volume":"12","author":"Weiner","year":"2012","journal-title":"Am J Transplant."},{"issue":"6","key":"B38-20251209","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant."},{"issue":"8","key":"B39-20251209","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant."},{"issue":"12","key":"B40-20251209","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1097\/TP.0000000000003192","article-title":"Assessing the complex causes of kidney allograft loss","volume":"104","author":"Van Loon","year":"2020","journal-title":"Transplantation."},{"issue":"8","key":"B41-20251209","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/gfac327","article-title":"A single centre in-depth analysis of death with a functioning kidney graft and reasons for overall graft failure","volume":"38","author":"Mayrdorfer","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B42-20251209","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.kint.2021.01.029","article-title":"Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies","volume":"100","author":"Senev","year":"2021","journal-title":"Kidney Int."},{"issue":"17","key":"B43-20251209","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA."},{"issue":"8","key":"B44-20251209","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"B45-20251209","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ki.2013.494","article-title":"Death from cancer: a sobering truth for patients with kidney transplants","volume":"85","author":"Wong","year":"2014","journal-title":"Kidney Int."},{"issue":"8","key":"B46-20251209","doi-asserted-by":"crossref","first-page":"e0272910","DOI":"10.1371\/journal.pone.0272910","article-title":"Risk of malignancy in patients with chronic kidney disease","volume":"17","author":"Tendulkar","year":"2022","journal-title":"PLoS One."},{"issue":"11","key":"B47-20251209","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2215\/CJN.15590920","article-title":"Chronic allograft injury","volume":"16","author":"Langewisch","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9800","key":"B48-20251209","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)60699-5","article-title":"Diagnosis and prevention of chronic kidney allograft loss","volume":"378","author":"Nankivell","year":"2011","journal-title":"Lancet."},{"issue":"10365","key":"B49-20251209","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet."},{"issue":"13","key":"B50-20251209","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J."},{"issue":"7","key":"B51-20251209","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/biomedicines11071867","article-title":"SGLT2 inhibitors as potential anticancer agents","volume":"11","author":"Basak","year":"2023","journal-title":"Biomedicines."},{"issue":"6","key":"B52-20251209","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab."},{"issue":"5","key":"B53-20251209","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"issue":"6","key":"B54-20251209","doi-asserted-by":"crossref","first-page":"101367","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metab."},{"issue":"12","key":"B55-20251209","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"B56-20251209","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"issue":"10","key":"B57-20251209","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.3390\/ijms23105634","article-title":"Role of sodium-glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models","volume":"23","author":"Feij\u00f3o-Band\u00edn","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B58-20251209","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem Pharmacol."},{"issue":"1","key":"B59-20251209","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12325-023-02652-5","article-title":"Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors","volume":"41","author":"Verma","year":"2024","journal-title":"Adv Ther."},{"issue":"12","key":"B60-20251209","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"B61-20251209","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia."},{"issue":"2","key":"B62-20251209","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am J Nephrol."},{"issue":"8","key":"B63-20251209","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00592-021-01681-2","article-title":"Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy","volume":"58","author":"Castoldi","year":"2021","journal-title":"Acta Diabetol."},{"issue":"1","key":"B64-20251209","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"B65-20251209","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant."},{"issue":"17","key":"B66-20251209","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.3390\/ijms21175954","article-title":"Recurrent glomerulonephritis after renal transplantation: the clinical problem","volume":"21","author":"Infante","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"10","key":"B67-20251209","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia."},{"issue":"4","key":"B68-20251209","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00182077","article-title":"Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation","volume":"14","author":"Modlin","year":"1996","journal-title":"World J Urol."},{"issue":"6","key":"B69-20251209","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/nu10060729","article-title":"Serum magnesium after kidney transplantation: a systematic review","volume":"10","author":"Garnier","year":"2018","journal-title":"Nutrients."},{"issue":"12","key":"B70-20251209","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B71-20251209","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of Empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care."},{"issue":"5","key":"B72-20251209","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients","volume":"13","author":"Ramakrishnan","year":"2023","journal-title":"World J Transplant."},{"issue":"23","key":"B73-20251209","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B74-20251209","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"B75-20251209","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant."},{"key":"B76-20251209","doi-asserted-by":"crossref","first-page":"1237583","DOI":"10.3389\/fphar.2023.1237583","article-title":"Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials","volume":"14","author":"Du","year":"2023","journal-title":"Front Pharmacol."},{"issue":"10","key":"B77-20251209","doi-asserted-by":"crossref","first-page":"e2236123","DOI":"10.1001\/jamanetworkopen.2022.36123","article-title":"Association of finerenone use with reduction in treatment-emergent pneumonia and COVID-19 adverse events among patients with type 2 diabetes and chronic kidney disease: a FIDELITY pooled secondary analysis","volume":"5","author":"Pitt","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"1","key":"B78-20251209","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","author":"Barrera-Chimal","year":"2013","journal-title":"Kidney Int."},{"issue":"5","key":"B79-20251209","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension."},{"issue":"2","key":"B80-20251209","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2014121216","article-title":"Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia","volume":"27","author":"Barrera-Chimal","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B81-20251209","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"P\u00e9rez-Rojas","year":"2005","journal-title":"Am J Physiol Renal Physiol."},{"issue":"9","key":"B82-20251209","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/ndt\/gfn204","article-title":"Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats","volume":"23","author":"Nielsen","year":"2008","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B83-20251209","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int."},{"issue":"1","key":"B84-20251209","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1152\/ajprenal.00147.2006","article-title":"Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity","volume":"292","author":"P\u00e9rez-Rojas","year":"2007","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"B85-20251209","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"B86-20251209","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev."},{"issue":"12","key":"B87-20251209","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/ndt\/gfy065","article-title":"Mineralocorticoid receptor antagonists in kidney transplantation: time to consider?","volume":"33","author":"Girerd","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B88-20251209","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","article-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial","volume":"4","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"B89-20251209","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B90-20251209","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.transproceed.2017.01.075","article-title":"Spironolactone in post-transplant proteinuria: a safe alternative therapy","volume":"49","author":"de Sousa","year":"2017","journal-title":"Transplant Proc."},{"issue":"suppl 3","key":"B91-20251209","first-page":"i886","article-title":"FC 118: the effect of spironolactone on calcineurin inhibitor induced nephrotoxicity\u2014the spiren trial","volume":"37","author":"Aas Mortensen","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B92-20251209","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"B93-20251209","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"B94-20251209","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"B95-20251209","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin Emerg Drugs."},{"issue":"8","key":"B96-20251209","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ajt.2023.04.025","article-title":"Recipient race modifies the association between obesity and long-term graft outcomes after kidney transplantation","volume":"23","author":"Jarrar","year":"2023","journal-title":"Am J Transplant."},{"issue":"10019","key":"B97-20251209","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet."},{"key":"B98-20251209","doi-asserted-by":"crossref","first-page":"935180","DOI":"10.3389\/fendo.2022.935180","article-title":"Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"B99-20251209","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care."},{"issue":"2","key":"B100-20251209","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","article-title":"Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts","volume":"46","author":"Thompson","year":"2023","journal-title":"Diabetes Care."},{"key":"B101-20251209","doi-asserted-by":"crossref","first-page":"1534365","DOI":"10.1155\/2019\/1534365","article-title":"Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"J Diabetes Res."},{"issue":"7","key":"B102-20251209","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"3-4","key":"B103-20251209","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud."},{"key":"B104-20251209","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"B105-20251209","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B106-20251209","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res."},{"issue":"10","key":"B107-20251209","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1210\/clinem\/dgad177","article-title":"Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes","volume":"108","author":"Sato","year":"2023","journal-title":"J Clin Endocrinol Metab."},{"key":"B108-20251209","first-page":"100343","article-title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or post-transplant diabetes","volume":"36","author":"Mahzari","year":"2024","journal-title":"J Clin Transl Endocrinol."},{"issue":"8","key":"B109-20251209","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.transproceed.2018.03.087","article-title":"Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study","volume":"50","author":"Liou","year":"2018","journal-title":"Transplant Proc."},{"issue":"4","key":"B110-20251209","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/15269248221122867","article-title":"Single-center evaluation of safety & efficacy of glucagon-like peptide-1 receptor agonists in solid organ transplantation","volume":"32","author":"Sweiss","year":"2022","journal-title":"Prog Transplant."},{"issue":"2","key":"B111-20251209","doi-asserted-by":"crossref","first-page":"sfae018","DOI":"10.1093\/ckj\/sfae018","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis","volume":"17","author":"Krisanapan","year":"2024","journal-title":"Clin Kidney J."},{"issue":"6","key":"B112-20251209","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/10600280231198925","article-title":"Sparsentan: a first-in-class dual endothelin and angiotensin II receptor antagonist","volume":"58","author":"Chiu","year":"2024","journal-title":"Ann Pharmacother."},{"issue":"10417","key":"B113-20251209","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet."},{"issue":"11","key":"B114-20251209","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan","year":"2024","journal-title":"Clin Sci (Lond)."},{"issue":"4","key":"B115-20251209","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1681\/ASN.2021111517","article-title":"Premature death in kidney transplant recipients: the time for trials is now","volume":"33","author":"Vinson","year":"2022","journal-title":"J Am Soc Nephrol."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:52:03Z","timestamp":1786132323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":114,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000726","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}